Mesoporous Manganese Nanocarrier Target Delivery Metformin for the Co-Activation STING Pathway to Overcome Immunotherapy Resistance

Yuanyao Dou,Jie Zheng,Jun Kang,Liping Wang,Daijuan Huang,Yihui Liu,Chao He,Caiyu Lin,Conghua Lu,Di Wu,Rui Han,Li,Liling Tang,Yong He
DOI: https://doi.org/10.1016/j.isci.2024.110150
IF: 5.8
2024-01-01
iScience
Abstract:Targeting the stimulator of interferon genes (STING) pathway is a promising strategy to overcome primary resistance to immune checkpoint inhibitors in non-small-cell lung cancer with the STK11 mutation. We previously found metformin enhances the STING pathway and thus promotes immune response. However, its low concentration in tumors limits its clinical use. Here, we constructed high-mesoporous Mn-based nanocarrier loading metformin nanoparticles (Mn-MSN@Met-M NPs) that actively target tumors and respond to release higher concentration of Mn2+ ions and metformin. The NPs significantly enhanced the T cells to kill lung cancer cells with the STK11 mutant. The mechanism shows that enhanced STING pathway activation promotes STING, TBKI, and IRF3 phosphorylation through Mn2+ ions and metformin release from NPs, thus boosting type I interferon production. In vivo, NPs in combination with a PD-1 inhibitor effectively decreased tumor growth. Collectively, we developed a Mn-MSN@Met-M nano-activator to intensify immune activation for potential cancer immunotherapy.
What problem does this paper attempt to address?